Genomic biomarkers androgen pathway and prostate cancer

Pharmacogenomics

Volumn 8, Issue 6, 2007, Pages 645-661

  D'Amico, Franca ^a   Biancolella, Michela ^a   Margiotti, Katia ^b   Reichardt, Juergen K V ^c   Novelli, Giuseppe ^a,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Androgen pathway; Androgen receptor; CYP17; CYP19; HSD3B2; Prostate cancer; SNP; Somatic mutation; SRD5A; Steroid 5 reductase

Indexed keywords

ALANINE; ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; BIOLOGICAL MARKER; CYTOCHROME P450 17; DNA; LEUCINE; OXYGENASE; POLYPEPTIDE; STEROID 5ALPHA REDUCTASE; STEROID DELTA ISOMERASE; STEROID REDUCTASE; THREONINE; VALINE;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CANCER PATIENT; COMPARATIVE GENOMIC HYBRIDIZATION; DNA FINGERPRINTING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM LINE; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT CARE; PATIENT MONITORING; PROGNOSIS; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ANDROGENS; GENETIC MARKERS; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 34250639425     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.6.645     Document Type: Review

References (138)

1. Jemai A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J. Clin. 57, 43-66 (2007).
2. Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60-67 (2000).
3. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413 (2006).
4. Carter BS, Carter HB, Isaacs JT: Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16(3), 187-197 (1990).
5. Carter BS. Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc. Natl Acad. Sci. USA 89(8), 3367-3371 (1992).
6. Visakorpi T: The molecular genetics of prostate cancer. Urology 62(Suppl. 1), 3-10 (2003).
7. Smith JR, Freije D, Carpten JD et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274(5291), 1371-1374 (1996).
8. Berthon P, Valeri A, Cohen-Akenine A et al.: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am. J. Hum. Genet. 62(6), 1416-1424 (1998).
9. Gibbs M, Stanford JL, McIndoe RA et al.: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am. J. Hum. Genet. 64 (3), 776-787 (1999).
10. Xu J, Zheng SL, Hawkins GA et al.: Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am. J. Hum, Genet. 69(2), 341-350 (2001).
11. Tavtigian SV, Simard J, Teng DH et al.: A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27 (2), 172-180 (2001).
12. Berry R, Schroeder JJ, French AJ: Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am. J. Hum. Genet. 67(1), 82-91 (2000).
13. Carpten J, Nupponen N, Isaacs S et al: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181-184 (2002).
14. Deutsch E. Maggiorella L, Eschwege P. Bourhis J, Soria JC, Abdulkarim B: Environmental, genetic and molecular features of prostate cancer. Lancet Oncol. 5, 303-313 (2004).
15. Porkka KP. Visakorpi T: Molecular mechanisms of prostate cancer. Eur. Urol. 45, 683-691 (2004).
16. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2. J. Clin. Oncol. 22, 735-742 (2004).
17. Xu J. Zheng SL, Komiya A et al.: Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat. Genet. 32, 321-325 (2002).
18. Nupponen NN, Walien MJ, Ponciano, D et al.: Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes Chromosomes Cancer 39(2), 119-125 (2004).
19. Dumur CI, Dechsukhum C. Ware JL et al.: Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81, 260-269 (2003).
20. Yano S, Matsuyama H, Matsuda K, Matsumoto H, Yoshihiro S, Naito K: Accuracy of an array comparative genomic hybridization (CGH) technique in detecting DNA copy number aberrations: comparison with conventional CGH and loss of heterozygosity analysis in prostate cancer. Cancer Genet. Cytogenet. 150 (2). 122-171 (2004)
21. Von Knobloch R, Konrad L, Barth PJ et al.: Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin. Cancer Res. 10, 1064-1073 (2004).
22. Harkonen P, Kyllonen AP, Nordling S. Vihko P: Loss of heterozygosity In chromosomal region 16q24.3 associated with progression of prostatelcancer. Prostate 62, 267-274 (2005).
23. Fromont G, Vaieri A, Cher M et al.: Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer. Prostate 65, 341-346 (2005).
24. Torring N, Borre M, Sorensen KD, Andersen CL, Wiuf C, Orntoft TF: Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. Br. J. Cancer 96(3), 499-506 (2007).
25. Wu CP, Gu FL: The prostate in eunuchs. Prog. Clin. Biol. Res. 370, 249-255 (1991).
26. Pollard M. Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res. 51(13), 3610-3611 (1991).
27. Pollard M, Luckert PH: The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett. 59, 159-163 (1991).
28. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J. Steroid Biochem. Mol. Biol. 92, 255-264 (2004).
29. Van den Oord EJ, Neale BM: Will haplotype maps be useful for finding genes? Mol. Psychiatry 9(3), 227-236 (2004).
30. Ross, Bernstein L. Lobo RA: 5-α-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339(8798), 887-889 (1992).
31. Wu AH, Whittemore AS, Gallagher RP et al.: Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J. Natl Cancer Inst. 87, 652-661 (1995).
32. Davis DL, Russell DW. Unusual length polymorphism in human steroid 5-α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet. 2(6), 820 (1993).
33. Kantoff PW, Febbo, PG. Giovannucci E et al.: A polymorphism, of the 5 α-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol. Biomarkers Prev. 6, 189-192 (1997).
34. Margiotti K, Sangiuolo F. De Luca A et al.: Evidence for an association between the SRD5A2 (type II steroid 5 α-reductase) locus and prostate cancer in Italian patients. Dis. Markers 16, 147-150 (2000).
35. Hsing AW, Chen C, Chokkalingam AP et al.: Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev., 10, 1077-1082 (2001).
36. Latil AG, Azzouzi R, Cancel GS et al.: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92, 1130-1137 (2001).
37. Makridakis N, Ross RK. Pike MC et al.: A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 57, 1020-1022 (1997).
38. Makridakis NM, di Salle E, Reichardt JK: Biochemical and pharmacogenetic dissection of human steroid 5 α-reductase type II. Pharmacogenetics 10, 407-4013 (2000).
39. Crawford ED: Epidemiology of prostate cancer. Urology 62, 3-12 (2003).
40. Febbo The V89L Polymorphism in the 5α-reductase type 2 Gene and risk of prostate cancer. Cancer Res. 59, 5878-5881 (1999).
41. Jaffe JM, Malkowicz; SB, Walker AH: Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60, 1626-1630 (2000).
42. Makridakis NM, Ross RK, Pike MC et al.: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354, 975-978 (1999).
43. Mononen N, Ikonen T, Syriakoski K et al.: A missense substitution A49T in the steroid 5-α-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br.J. Cancer 84, 1344-1347 (2001).
44. Soderstrom T, Wadelius M, Andersson SO et al.: 5-α-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12, 307-312 (2002).
45. Ntais C, Polycarpou A. Ioannidis JP: SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 618-624 (2003).
46. Forrest MS, Edwards SM, Houlston R et al.: Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer frostatic Dis. 8 (1), 95-102 (2005).
47. Schatzi G, Madersbacher S, Temml C et al.: Serum androgen levels in men: impact of health status and age. Urology 61, 629-633 (2003).
48. Loukola A, Chadha M, Penn SG et al.: Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur. J. Hum. Genet. 12, 321-332 (2004).
49. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK: Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A42) gene and benign prostatic hyperplasia and prostate cancer. Urol. Oncol. 23, 246-253 (2005).
50. Giwercman YL, Abrahamsson PA. Giwercman A, Gadaleanu V, Ahlgren G: The 5α-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur. Urol. 48, 679-685 (2005).
51. Sobti RC, Onsory K, Al-Badran AI et al.: CYP17 SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA. Cell Biol. 25, 287-294 (2006).
52. Mononen N, Seppala EH, Duggal P: Profiling genetic variation along the androgen biosynthesis and metabolism pathways Implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res. 66, 743-747 (2006).
53. Akalu A, Dimajian DA, Highshaw RA, Nichols PW, Reichardt JK: Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5α-reductase during prostate cancer progression. J Urol. 161. 1355-1358 (1999).
54. Makridakis N, Akalu A, Reichardt JK: Identification and characterization of somatic steroid 5α-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23(44), 7399-7405 (2004).
55. Vermeulen A. Kaufman JM, Goemaere S, van Pottelberg I: Estradlol in elderly men. Aging Male 5 (2), 98-102 (2002).
56. Risbridger GR Bianco JJ, Ellem SJ, McPherson SJ: Oestrogens and prostate cancer. Endocr. Relat. Cancer 10(2), 187-191 (2003).
57. Ellem SJ. Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP: Local aromatase expression in human prostate is altered in malignancy. J Clin. Edocrinol. Metab. 89(5), 2434-2441 (2004).
58. Latil A, Bieche I, Vidaud D et al.: Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assay. Cancer Res. 61(5), 1919-1926 (2001).
59. Modugno F, Weissfeld JL, Trump D et al.: Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin. Cancer Res. 7(10), 3092-3096 (2001).
60. Suzuki K, Nakazato H, Matsui H et al.: Association of the genetic polymorphism of the CYP19intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res. 23(6D), 4941-4946 (2003).
61. Tsuchiya N, Wang L, Suzuki H et al.: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J. Clin. Oncol. 24. 1982-1989 (2006).
62. Li L, Cicek MS, Casey G: No association between a tetranucleoticle repeat polymorphism of CYP19 and prostate cancer Cancer Epidemiol. Biomarkers Prev. 13, 2280-2281 (2004).
63. Suzuki K,. Nakazato, H, Matsui H et al.: Genetic polymorphisms of estrogen receptor A, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98, 1411-1416 (2003).
64. Sauders CT, Baker D: Evaluation of structural and evolutionary contributions to deleterious mutation prediction. J. Mol. Blol. 322. 891-901 (2002).
65. Miller WL: Androgen blosynthesis from cholesterol to DHEA. Mol. Cell. Fndocrinol. 198, 7-14 (2002).
66. Strauss JF: Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann. NY Acad. Sci. 997, 42-48 (2003).
67. Ogo A, Haji M, Ohashi M, Nawata H: Markedly increased expression of cytochrome P-450 17α-hydroxylase (P-450c17) mRNA in adrenocortical adenomas from patients with Cushing's syndrome. Mol. Cell. Endocrinol. 80, 83-89 (1991).
68. Maitra A, Shirwalkar H: Congenital adrenal hyperplasia: biochemical and molecular perspectives. Indian J. Exp. Biol. 41, 701-709 (2003).
69. Lunn RM, Bell DA, Mohler JL Taylor JA: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase ( SRD5A2). Carcinogenesis 20, 1727-1731 (1999).
70. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E: Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9. 635-639 (1999).
71. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE: A cytochrome p450c17a gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res, 58, 585-587 (1998).
72. Kristensen VN, Haraldsen EK, Anderson KB et al.: CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 59, 2825-2828 (1999).
73. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE: A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57, 1063-1065 (1997).
74. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S: Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int. J. Cancer 84, 350-353 (1999).
75. Young IE, Kurian KM, Annink C et al.: A polymorphism in the CYP17 gene is associated with male breast cancer. Br. J. Cancer 81, 141-143 (1999).
76. Lunn RM, Bell DA, Mohler JL, Taylor JA: Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase ( SRD5A2). Carcinogenesis 20, 1727-1731 (1999).
77. Cicek MS. Conti DV, Curran A et al.: Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59, 69-76 (2004).
78. Habuchi T, Liqing Z, Suzuki T et al.: Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60, 5710-5713 (2000).
79. Ntais C, Polycarpou A, Ioannidis JP: Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12. 120-126 (2003).
80. Stanford JL, Noonan EA, Iwasaki L et al.: A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol. Biomarkers. Prev. 11, 243-247 (2002).
81. Douglas JA, Zuhlke KA, Beebe-Dimmer J et al.: Identifying susceptibility genes for prostate cancer - a family-based association study of polymorphisms in CYP 17. CYP 19. CYP11A 1, and LH-β. Cancer Epidemiol. Biomarkers Prev. 14, 2035-2039 (2005).
82. Vesovic Z, Herkommer K, Vogel W: Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res. 25. 1303-1307 (2005).
83. Antognelli C. Mearini L, Talesa VN: Association of CYP 17, GSTP 1. and PON1 polymorphisms with the risk of prostate cancer. Prostate 63, 240-251 (2005).
84. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E: Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9, 635-639 (1999).
85. Verreault H. Dufort I. Simard J, Labrie F, Luu-The V: Dinucleoticle repeat polymorphisms in the HSD3B2 gene. Hum. Mol. Cenet. 3, 384 (1994).
86. Devgan SA, Henderson BE, Yu MC et al.: Genetic variation of 3 β-hydroxysteroid dehydrogenase type II in three raclal/ethnic groups: implications for prostate cancer risk. Prostate 33, 9-12 (1997).
87. Chang BL, Zheng SL. Hawkins GA et al.: joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res. 62, 1784-1789 (2002).
88. Berndt WI et al.: Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16, 165-168 (2007).
89. Stanbrough M, Bubley GJ, Ross L: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815-2825 (2006).
90. Edwards A, Hammond HA. Jin L, Caskey CT, Chakraborty R: Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12, 241-253 (1992)
91. Giovannucci E, Stampfer MJ, Krithivas K et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA 94, 3320-3323 (1997).
92. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
93. Mhatre AN, Trifiro MA, Kaufman M et al.: Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Cene. 5, 184-188 (1993).
94. Chamberlain NL. Driver ED, Miesfeid RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186 (1994).
95. Kazemi-Esfarjani P, Trifiro MA, Pinsky L: Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum. Mol. Genet. 4, 523-527 (1995).
96. Bellin J, Ban EM, Favaloro JM, Zajac JD: Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25, 85-96 (2000).
97. Buchanan G. Yang M, Cheong A et al.: Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum. Mol. Genet. 13, 1677 (2004)
98. Irvine RA, Yu MC, Ross R: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55. 1937-1940 (1995).
99. Ding D, Xu L, Menon M, Reddy GP, Barrak ER: Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62, 133-139 (2005).
100. Hardy DO, Scher HI, Bogenreider T et al.: Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin. Endocrinol. Metab. 81, 4400-4405 (1996).
101. Sartor O, Zheng Q, Eastham JA: Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53, 378-380 (1999).
102. Mishra D, Thangaraj K, Mandhani A: Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? Clin. Genet. 68, 55-60 (2005).
103. Krishnaswamy Y. Kumarasamy T, Venkatesan V, Shroff S, Jayanth VR, Paul SF: South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J. Hum. Genet. 51, 254-257 (2006).
104. Chen C, Lamharzi N, Weiss NS et al.: Androgen receptor polymorphisnis and the incidence of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1033-1040 (2002).
105. Chang BL, Zheng SL, Hawkins GA et al.: Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum. Genet. 110, 122-129 (2002).
106. Gsur A, Preyer M, Haidinger G et al.: Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. Carcinogenesis 23, 1647-1651 (2002).
107. Suzuki H, Akakura K, Komiya A et al.: CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51. 219-224 (2002).
108. Freedman ML, Pearce CL, Penney KL et al.: Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multlethnic cohort study. Am. J. Hum. Genet. 76, 82-90 (2005).
109. Salinas CA, Austin MA, Ostrander EO Stanford JL: Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 65, 58-65 (2005).
110. Lindström S, Zheng SL, Wiklund F et al.: Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 66 (16). 17296-17243 (2006).
111. Zeegers W, Kiemeney LA, Nieder AM, Ostrer H: How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol. Biomarkers Prev. 13, 1765-1771 (2004).
112. Mononen N, Syrjakoski K, Matikainen M et al.: Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res. 60, 6479-6481 (2000).
113. Gruber SB, Chen H, Tomsho LP: R726L Androgen receptor mutation is uncommon in prostate cancer families in the United States. Prostate 54, 306-309 (2003).
114. Lu J, Danielsen M: A StuI Polymorphism in the human androgen receptor gene (AR). Clin. Genet. 49, 323-324 (1996).
115. Ross RK, Pike MC, Coetzee GA et al.: Androgen metabolism and prostate cancer:, Establishing a model of genetic susceptibility. Cancer Res. 58, 4497-4504 (1998).
116. Sasaki M, Nomoto M, Yonezawa S et al.: Distribution of a single nucleotide polymorphism on codon 211 of the androgen receptor gene and its correlation with human renal cell cancer in Japanese patients. Biochem. Biophys. Res. Commun. 321, 468-471 (2004).
117. Hayes M. Severi G, Eggleton SA: The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol. Biomarkers Prev. 14 (4), 993-996 (2005).
118. Lindstrom S, Wiklund F, Adami HO, Balter KA, Adolfsson J, Gronberg H: Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P 450, and steroid-5-α-reductase type 2 is important for prostate cancer development. Cancer Res. 66. 11077-11083 (2006).
119. Roehl KA, Han M, Ramos CG, Anterior JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J Urol. 172, 910-914 (2004).
120. Kinoshita H, Shi Y, Sandefur C et al.: Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60(13), 3623-3630(2000).
121. Avila DM, Zoppi S, McPhaul MJ: The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer J. Steroid Biochem. Mol Biol. 76(1-5), 135-142 (2001).
122. Visakorpi T, Hyytinen E, Koivisto P et al.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 9, 401-406 (1995).
123. Heinlein CA, Chang C: The roles of androgen receptors and androgen-binding proteins in nongenontic androgen actions. Mol. Endocrinol. 16, 2181-2187 (2002).
124. Scher HI, Buchanan G, Gerald W, Butler LM Tilley WD: Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 11. 459-476 (2004).
125. Gottlieb B, Beitei LK, Wu JH, Trifiro M: The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 23(6), 527-533 (2004).
126. Veldscholte J. Ris-Stalpers C, Kuiper GG et al.: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540 (1990).
127. Hyytinen ER, Haapaia K. Thompson J et al.: Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab, Invest. 82. 1591-1598 (2002).
128. Thompson J, Hyytinen ER, Haapala K et al.: Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab. Invest. 83, 1709-1713 (2003).
129. Han G, Buchanan G, Ittmann M et al.: Mutation of the androgen receptor causes oncogenic transformation of the prostate Proc. Natl Acad. Sci USA 102, 1151-1156 (2005).
130. Sun C, Shi Y, Xu LL et al.: Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25, 3905-3913 (2006).
131. Shi XB, Xue L. Tepper CG et al.: The oncogenic potential of a prostate cancer-derived androgen receptor mutant. Prostate 67, 591-602 (2007).
132. Edwards J, Krishna NS, Mukherjee R: Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU Int. 88, 633-637 (2001).
133. Haapala K, Kuukasjarvi T, Hyytinen E. Rantala I, Helin HJ. Koivisto PA: Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum. Pathol. 38, 474-478 (2007).
134. Slager SL, Zarfas KE, Brown WM et al.: Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 66, 173-179 (2006).
135. Yeager M, Orr N. Hayes RB et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
136. Haiman AC, Patterson N, Freedman ML et al.: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638-644 (2007).
137. Gudmundsson J, Sulem P, Manolescu A et al.: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39. 631-637 (2007).
138. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H: Molecular markers for prostate cancer. Cancer Lett. 249, 5-13 (2007).